0001641489-25-000014 | 10-K | XBRL Viewer

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 6.B)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-11

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

+ Details

Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Segment Reporting Information [Line Items]

Research and development

$ 11,546

$ 13,595

^[1]

$ 12,357

^[1]

Reportable Segment

Segment Reporting Information [Line Items]

Indirect research and development expense

5,030

2,737

2,183

Research and development

11,546

13,595

12,357

Reportable Segment | Cadisegliatin

Segment Reporting Information [Line Items]

Direct research and development expense:

6,026

10,182

9,611

Reportable Segment | Other projects

Segment Reporting Information [Line Items]

Direct research and development expense:

$ 490

$ 676

$ 563

[1]	(*) Adjusted retroactively for reverse stock split

Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Number of Shares
Award outstanding, beginning balance (in shares) \| shares	249,247
Granted (in shares) \| shares	461,499
Forfeited (in shares) \| shares	(5,153)
Award outstanding, ending balance (in shares) \| shares	705,593
Options exercisable (in shares) \| shares	282,946
Weighted average remaining contractual term	7 years
Options vested and expected to vest (in shares) \| shares	602,671
Weighted average remaining contractual term	8 years 1 month 6 days
Weighted Average Exercise Price
Awards outstanding, beginning balance (usd per share) \| $ / shares	$ 77.53
Granted (usd per share) \| $ / shares	13.14
Forfeited (usd per share) \| $ / shares	18.75
Awards outstanding, ending balance (usd per share) \| $ / shares	35.85
Options exercisable (usd per share) \| $ / shares	66.16
Options vested and expected to vest (usd per share) \| $ / shares	$ 39.47

Consolidated Statements of Operations - USD ($)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

^[1]

Dec. 31, 2022

^[1]

Revenue

$ 1,017,000

$ 0

$ 2,018,000

Operating expenses:

Research and development

11,546,000

13,595,000

12,357,000

General and administrative

13,651,000

11,907,000

12,201,000

Total operating expenses

25,197,000

25,502,000

24,558,000

Operating loss

(24,180,000)

(25,502,000)

(22,540,000)

Interest income

1,565,000

472,000

352,000

Interest expense

(13,000)

(15,000)

Loss before income taxes and noncontrolling interest

(22,605,000)

(25,966,000)

(24,873,000)

Income tax provision

100,000

200,000

Net loss before noncontrolling interest

(22,705,000)

(25,966,000)

(25,073,000)

Less: net loss attributable to noncontrolling interest

(4,243,000)

(5,716,000)

(5,909,000)

Net loss attributable to vTv Therapeutics Inc.

(18,462,000)

(20,250,000)

(19,164,000)

Net loss attributable to vTv Therapeutics Inc. common shareholders

(18,462,000)

(20,250,000)

(19,164,000)

Nonrelated Party

Operating expenses:

Other income (expense), net

160,000

(1,497,000)

(3,616,000)

Related Party

Operating expenses:

Other income (expense), net

$ (150,000)

$ 574,000

$ 946,000

Class A Common Stock

Operating expenses:

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (usd per share)

$ (3.20)

$ (9.71)

$ (9.98)

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (usd per share)

$ (3.20)

$ (9.71)

$ (9.98)

Weighted average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)

5,771,052

2,084,973

1,919,788

Weighted average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)

5,771,052

2,084,973

1,919,788

[1]	(*) Adjusted retroactively for reverse stock split

Income Taxes

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Income Taxes

The Company is subject to U.S. federal income taxes as well as state taxes. The Company's income tax provision for the year ended December 31, 2024 and 2022 was $0.1 million and $0.2 million, respectively, representing foreign withholding taxes incurred in connection with payments received under license agreements with foreign entities. The Company did not record an income tax provision for the year ended December 31, 2023.

Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more likely than not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on December 31, 2024 is due to the valuation allowance against the Company’s expected net operating losses.

As discussed in Note 13, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of December 31, 2024.

In August 2022, the Inflation Reduction Act (“IRA”) and CHIPS and Science Act (“CHIPS Act”) were both enacted. This new legislation includes the implementation of a new corporate alternative minimum tax, an excise tax on stock buybacks, and tax incentives for energy and climate initiatives, among other provisions. The income tax provisions of the IRA or the CHIPS Act had limited applicability to the Company and did not have a material impact on the Company’s consolidated financial statements.

A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands):


	December 31,
	2024			2023			2022
U.S. statutory tax benefit	$	(4,747)		$	(5,453)		$	(5,223)
Partnership income (federal) not subject to tax to the Company	891			1,200			1,241
Foreign withholding tax	79			—			158
State taxes (net of federal benefit)	(928)			(2)			28
Research and development tax credit	(373)			(273)			(172)
Other	190			(64)			40
Change in valuation allowance	4,988			4,592			4,128
Provision for income taxes	$	100		$	—		$	200
Effective income tax rate	(0.4)		%	0.0		%	(0.8)		%

Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands):


	December 31,
	2024		2023
Deferred tax assets:
Net operating loss carryforwards	$	27,819	$	23,718
R&D Tax Credit carryforwards	2,491		2,215
Investment in partnerships	3,322		2,726
Charitable contributions	2		3
Capital loss carryforward	395		380
Total deferred tax assets	34,030		29,042
Valuation allowance	(34,030)		(29,042)
Net deferred tax assets	$	—	$	—

The Company assesses the available positive evidence and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of existing deferred tax assets. A significant piece of objective negative evidence evaluated was the Company’s recent operating losses. Such objective evidence limits the ability to consider other subjective evidence, such as forecasts of profitability. Based on the weight of objective evidence, including cumulative pre-tax losses in recent years, the Company concluded that its deferred tax assets were not realizable on a more-likely-than-not basis and recorded a full valuation allowance. During the year ended December 31, 2024, the Company’s valuation allowance increased by $5.0 million.

The Company has federal net operating loss carryforwards of $125.8 million that will be available to offset future taxable income. Approximately, $38.8 million of these carryforwards expire in varying amounts starting in 2035 to 2037, if not utilized and are available to offset 100% of future taxable income. The remaining $86.9 million may be carried forward indefinitely but are only available to offset 80% of future taxable income. The Company has federal research and development tax credits of $2.5 million which expire in varying amounts starting in 2035 to 2043. In addition, the Company

has North Carolina net operating loss carryforwards of approximately $59.7 million which are set to expire beginning in 2030 through 2039.

The Company applies applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its consolidated financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2024, the Company had no uncertain tax positions. There are no uncertain tax positions for which it is reasonably possible that the total amount of unrecognized tax benefits will significantly increase or decrease within twelve months of December 31, 2024.

The Company files U.S. federal income tax returns and income tax returns in various state and local jurisdictions. The earliest open tax years that are still subject to examination by the IRS and the aforementioned state tax authorities are 2021 to 2024.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Share-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement [Abstract]

Assumptions Used to Estimate Fair Value of Stock Option Awards Granted

The Company uses the Black-Scholes option pricing model to calculate the fair value of stock options granted. The fair value of stock options granted was estimated using the following assumptions during the years ended December 31, 2024, 2023 and 2022:


	For the Year Ended December 31,
	2024	2023	2022
Expected volatility	96.84% - 108.61%	121.01% - 126.76%	118.72% - 128.72%
Expected life of option, in years	5.5 - 6.1	5.5 - 6.1	5.2 - 6.1
Risk-free interest rate	3.44% - 4.36%	3.42% - 4.61%	1.59% - 4.31%
Expected dividend yield	0.00%	0.00%	0.00%

Summary of Stock Award Activity for the Period

The following table summarizes the activity related to the stock option awards for the year ended December 31, 2024 (in thousands, except per share amounts):


	Number of Shares	Weighted Average Exercise Price
Awards outstanding at December 31, 2023	249,247	$	77.53
Granted	461,499	13.14

Forfeited	(5,153)	18.75
Awards outstanding at December 31, 2024	705,593	$	35.85
Options exercisable at December 31, 2024	282,946	$	66.16
Weighted average remaining contractual term	7.0 Years
Options vested and expected to vest at December 31, 2024	602,671	$	39.47
Weighted average remaining contractual term	8.1 Years

Summary of Compensation Expense Related to Grants of Stock Options

Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):


	2024		2023		2022
Research and development	$	742	$	425	$	406
General and administrative	2,015		1,153		866
Total share-based compensation expense	$	2,757	$	1,578	$	1,272

Income Taxes - Schedule of Net Deferred Tax Assets/(Liabilities) (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Net operating loss carryforwards	$ 27,819	$ 23,718
R&D Tax Credit carryforwards	2,491	2,215
Investment in partnerships	3,322	2,726
Charitable contributions	2	3
Capital loss carryforward	395	380
Total deferred tax assets	34,030	29,042
Valuation allowance	(34,030)	(29,042)
Net deferred tax assets	$ 0	$ 0

Accounts Payable and Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Liabilities

Accounts payable and accrued expenses consist of the following (in thousands):


	December 31,
	2024		2023
Accounts payable	$	939	$	4,075
Accrued development costs	2,263		4,401
Accrued compensation and related costs	1,509		1,466
Accrued other	316		300
Total	$	5,027	$	10,242

Fair Value of Financial Instruments - Assumption Used to Calculate Fair Value of Warrants (Detail)	Dec. 31, 2024	Dec. 31, 2023
CinRx Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected life of options in years	2 years 6 months	3 years 6 months
Expected volatility \| CinRx Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.965	0.821
Risk-free interest rate \| CinRx Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.043	0.040
Expected dividend yield \| CinRx Warrants
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0	0
Minimum \| Expected volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.8801	0.7996
Minimum \| Risk-free interest rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.0417	0.0401
Maximum \| Expected volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	1.1631	0.8961
Maximum \| Risk-free interest rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.0425	0.0487
Weighted Average \| Expected volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	1.0597	0.8155
Weighted Average \| Risk-free interest rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Inputs utilized in the valuation of warrants	0.0423	0.0415

Related-Party Transactions (Tables)

12 Months Ended

Dec. 31, 2024

Summary of Terms of Letter Agreements

Certain terms of these Letter Agreements are set forth in the tables below:


	December 5, 2017 Letter Agreement		July 30, 2018 Letter Agreement		December 11, 2018 Letter Agreement		March 18, 2019 Letter Agreement		September 26, 2019 Letter Agreement		December 23, 2019 Letter Agreement
Aggregate dollar value to be sold under agreement	$10.0 million		$10.0 million		$10.0 million		$9.0 million		$10.0 million		$10.0 million
Specified purchase price per share	$	175.20	$	53.20	$	73.60	$	66.00	$	58.40	$	64.00
Expiration date of letter agreement	December 5, 2018		July 30, 2019		December 11, 2019		March 18, 2020		September 26, 2020		December 23, 2020
Shares available to be issued under related warrants	4,956		12,966		8,513		—		10,024		9,136
Exercise price of related warrants	$	201.60	$	61.20	$	84.80	$	—	$	67.20	$	73.60
Expiration date of related warrants	December 5, 2024		July 30, 2025		December 11, 2025				September 26, 2026		December 23, 2026
Total shares issued as of December 31, 2024	57,077		187,969		135,869		136,363		171,232		156,250
Remaining shares to be issued as of December 31, 2024	—		—		—		—		—		—

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2024

Prepaid Expense and Other Assets, Current [Abstract]

Summary of Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	December 31,
	2024		2023
Prepaid insurance	$	577	$	680


Prepaid - other	643		364
Total	$	1,220	$	1,044

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings. Novo Nordisk In February 2007, the Company entered into an Agreement (the “Novo License Agreement”) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo Nordisk”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as cadisegliatin. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and non-specific areas of therapeutic use. Under the terms of the Novo License Agreement, the Company has additional potential developmental and regulatory milestone payments totaling up to $7.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products.

Leases - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Renewal term	5 years
Termination period	3 years
Weighted average incremental borrowing rate	9.50%	9.50%
Remaining operating lease term	10 months 24 days	1 year 10 months 24 days
Operating lease cost	$ 0.2	$ 0.2	$ 0.2
Cash paid for operating lease	$ 0.2	$ 0.2

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment [Abstract]

Summary of Property and Equipment

Property and equipment consists of the following (in thousands):


	December 31,
	2024		2023
Leasehold improvements	$	406	$	406
Computers and hardware	69		69
Software	12		80
Furniture and office equipment	49		49
Total property and equipment	536		604
Less: accumulated depreciation and amortization	(508)		(487)
Property and equipment, net	$	28	$	117

Employee Benefit Plan	12 Months Ended
Employee Benefit Plan	Dec. 31, 2024
Retirement Benefits [Abstract]
Employee Benefit Plan	Employee Benefit Plan The Company has a 401(k)-retirement plan in which all of its full-time employees are eligible to participate. The plan provides for the Company to make discretionary 50% matching contributions up to a maximum of 6% of employees’ eligible compensation. The Company contributed $0.1 million to the plan for each of the years ended December 31, 2024 and 2023. The Company contributed a de minimis amount to the plan for the year ended December 31, 2022.

Share-Based Compensation

12 Months Ended

Dec. 31, 2024

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation

The Company has issued non-qualified stock option awards to management, other key employees, consultants, and nonemployee directors and these options vest ratably over a four-year period. In addition, we issued options in connection with the private placement on February 27, 2024, that vest ratably over a three-year period. The option awards expire after a term of ten years from the date of grant. For the years ended December 31, 2024, 2023 and 2022, the Company recognized $2.8 million, $1.6 million and $1.3 million, respectively, of compensation expense related to share-based awards. Given that the Company has established a full valuation allowance against its deferred tax assets, the Company has recognized no tax benefit related to these awards. As of December 31, 2024, the Company had total unrecognized stock-based compensation expense of approximately $4.7 million, which is expected to be recognized on a straight-line basis over a weighted average period of 2.3 years. The weighted average grant date fair value for all option grants during the years ended December 31, 2024, 2023 and 2022 was $14.76, $24.78 and $27.75 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding as well as those exercisable as of December 31, 2024, was an insignificant amount. The total fair value of stock options vested during the years ended December 31, 2024, 2023 and 2022 was $2.9 million, $2.2 million and $1.5 million, respectively.

On February 23, 2024, in connection with the Private Placement, several directors resigned as members of the Company’s Board of Directors, effective on the closing of the Private Placement. As a result of their resignations, 14,340 stock options to purchase shares of common stock were modified to increase the time period to exercise the options and 7,590 stock options to purchase shares of common stock were modified to accelerate vesting at the termination date. All the unvested options were modified to be fully vested as of the posting of the Private Placement which resulted in a reduction in their fair value. The Company incurred $0.1 million reduction in stock compensation expense for the modifications for the year ended December 31, 2024.


	For the Year Ended December 31,
	2024	2023	2022
Expected volatility	96.84% - 108.61%	121.01% - 126.76%	118.72% - 128.72%
Expected life of option, in years	5.5 - 6.1	5.5 - 6.1	5.2 - 6.1
Risk-free interest rate	3.44% - 4.36%	3.42% - 4.61%	1.59% - 4.31%
Expected dividend yield	0.00%	0.00%	0.00%

The following table summarizes the activity related to the stock option awards for the year ended December 31, 2024 (in thousands, except per share amounts):


	Number of Shares	Weighted Average Exercise Price
Awards outstanding at December 31, 2023	249,247	$	77.53
Granted	461,499	13.14

Forfeited	(5,153)	18.75
Awards outstanding at December 31, 2024	705,593	$	35.85
Options exercisable at December 31, 2024	282,946	$	66.16
Weighted average remaining contractual term	7.0 Years
Options vested and expected to vest at December 31, 2024	602,671	$	39.47
Weighted average remaining contractual term	8.1 Years

Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):


	2024		2023		2022
Research and development	$	742	$	425	$	406
General and administrative	2,015		1,153		866
Total share-based compensation expense	$	2,757	$	1,578	$	1,272

Leases (Tables)

12 Months Ended

Dec. 31, 2024

Leases [Abstract]

Schedule of Maturities of Lease Liabilities for Operating Leases

Maturities of lease liabilities for the Company’s operating leases as of December 31, 2024, were as follows (in thousands):


2025	$	177
2026	—
2027	—
2028	—
2029	—
Thereafter	—
Total lease payments	177
Less: imputed interest	(8)
Present value of lease liabilities	$	169

Collaboration Agreements

12 Months Ended

Dec. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaboration Agreements

G42 Purchase Agreement and Cogna Collaborative and License Agreement

The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”), on May 31, 2022, pursuant to which the Company sold to G42 Investments 259,657 shares of the Company’s Class A common stock, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the "G42 Promissory Note"). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other (expense)/income in the Company’s Consolidated Statements of Operations.

G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024 (or if earlier, the date of receipt of U.S. Food and Drug Administration (“FDA”) approval in the U.S. for cadisegliatin (TTP399), the Company has granted to G42 Investments

certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.

Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”), which requires Cogna to work with the Company in performing clinical trials for cadisegliatin (TP399) as well as jointly creating a global development plan to develop, market, and commercialize cadisegliatin in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize cadisegliatin in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and cadisegliatin. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of cadisegliatin needed to conduct the trials.

Under the Cogna Agreement, Cogna has the right to develop and commercialize cadisegliatin in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, cadisegliatin for commercial sale under terms to be agreed upon by the parties at a later date.

Separately, the Company will conduct its clinical trials for cadisegliatin outside of the Partner Territory at its own cost. The results of each party’s clinical trials may be combined by the Company to seek FDA approval in the United States for cadisegliatin. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna Agreement to G42 Healthcare Research Technology Projects LLC ("G42 Healthcare"), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.

The G42 Purchase Agreement also provides for, following the receipt of the cadisegliatin FDA Approval, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the cadisegliatin FDA Approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the cadisegliatin FDA Approval will be granted or as to the timing thereof.

Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of cadisegliatin for a period of at least ten years after the first commercial sale of cadisegliatin in the Partner Territory.

A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.

The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of cadisegliatin, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete research and development activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.

By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall within the ASC 808 unit of account are concentrated in the clinical trials. As of December 31, 2024, the clinical trials had not

commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the year ended December 31, 2024.

The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after cadisegliatin is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the years ended December 31, 2024 and 2023.

On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other (expense) income in the Company’s Consolidated Statements of Operations. The G42 Promissory Note receivable was classified and accounted for under ASC 310 Receivables (“ASC 310”) and was initially measured at its fair value of $11.9 million. The Company also recorded the $18.7 million as deferred revenue in the Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the years ended December 31, 2024 and 2023. On February 27, 2024, the Company and G42 Investments further amended the G42 Purchase Agreement in connection with the Private Placement.

Huadong License Agreement

The Company was a party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. Under the terms of the Huadong License Agreement, as amended, Huadong paid the Company an initial license fee of $8.0 million and was obligated to pay potential development and regulatory milestone payments totaling up to $22.0 million, with an additional potential regulatory milestone of $20.0 million if Huadong had received regulatory approval for a central nervous system indication. In addition, the Company was eligible for an additional $50.0 million in potential sales-based milestones, as well as royalty payments ranging from low-single to low-double digit rates, based on tiered sales of licensed products.

On January 14, 2021, the Company entered into the first amendment to the Huadong License Agreement ("First Huadong Amendment") which eliminated the Company’s obligation to sponsor a multi-region clinical trial (the “Phase 2 MRCT”), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.

Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC 606 and performed a reallocation of the transaction price among the remaining performance obligations. This resulted in the recognition of approximately $1.0 million of revenue on a cumulative catch up basis during the year ended December 31, 2021. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.

The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company’s obligation to participate on the JDC, and (iv) other obligations considered to be immaterial in nature.

The Company determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. In the first quarter of 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during the year ended December 31, 2022 as the related performance obligation was fully satisfied. No revenue related to this combined performance obligation was recognized during the year ended December 31, 2024.

A portion of the transaction price was allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan. The revenue was recognized using the proportional performance model over the period of the Company’s participation on the JDC. An immaterial amount of revenue for this performance obligation was recognized during the years ended December 31, 2024 and 2022. No revenue was recognized during the year ended December 31, 2023. The full transaction price has been recognized as of December 31, 2024.

On December 18, 2023, vTv LLC received notice from Huadong of their intent to terminate the Huadong License Agreement between vTv LLC and Huadong, dated as of December 21, 2017, as amended on January 14, 2021 (both together constituting the "Agreement"). The termination of the Agreement was effective September 1, 2024.

Newsoara License Agreement

On May 31, 2018, the Company entered into a license agreement with Newsoara Biopharma Co., Ltd., (“Newsoara”) (the “Newsoara License Agreement”), under which Newsoara obtained an exclusive and sublicensable license to develop and commercialize the Company’s phosphodiesterase type 4 inhibitors (“PDE4”) program, including the compound HPP737, in China and other Pacific Rim territories (collectively, the “Newsoara License Territory”). Additionally, under the Newsoara License Agreement, the Company obtained a non-exclusive, sublicensable, royalty-free license to develop and commercialize certain Newsoara patent rights and know-how related to the Company’s PDE4 program for therapeutic uses in humans outside of the Newsoara License Territory.

The Newsoara License Agreement was amended in 2020 to change certain future milestone payments and patent rights (the “First Newsoara Amendment”). Under the terms of the Newsoara License Agreement, Newsoara paid the Company an upfront cash payment of $2.0 million. During the year ended December 31, 2019, the Company received an additional payment of $1.0 million related to the satisfaction of a development milestone during the year. On June 26, 2024, the Company entered into the second amendment to the Newsoara License Agreement (the “Second Newsoara Amendment”) which expanded the global license contingent upon Newsoara paying an upfront global rights fee (the “Upfront Fees”) of $20.0 million. Newsoara has up to one year from the date of the Second Newsoara Amendment to pay the Upfront Fees; if it fails to do so, then the Second Newsoara Amendment will be null and void. As amended, the Company is eligible to receive additional potential development, regulatory and sales-based milestone payments totaling up to $76.5 million. In addition, Newsoara is obligated to pay the Company royalty payments at mid to upper single digit rates, based on tiers of annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product and country-by-country basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country or a specified number of years after the first commercial sale of a licensed product in a country. There are no new performance obligations to be considered within the Second Newsoara Amendment. The Second Amendment has a potential impact to increase the transaction price by $20.0 million. If the Company receives the Upfront Fees, $20.0 million of revenue will be recognized at a point in time.

Pursuant to the terms of the Newsoara License Agreement, the Company is required to provide technology transfer services for a defined period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Newsoara License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and the related revenue was recognized during the year ended December 31, 2018.

In the first quarter of 2024, the transaction price for this performance obligation was increased by $1.0 million due to the satisfaction of a development milestone under the Newsoara License Agreement. This amount was fully recognized as revenue during the year ended December 31, 2024, as the related performance obligation was fully satisfied. No revenue related to this performance obligation was recognized and there were no changes to the transaction price during the years ended December 31, 2023 and 2022.

The remaining milestone payments that the Company is eligible to receive have not been included in the transaction price as of December 31, 2024, as it is not considered probable that such payments will be received.

Contract Liabilities


	December 31, 2024		December 31, 2023
Current portion of contract liabilities	$	—	$	17
Contract liabilities, net of current portion	18,669		18,669
Total contract liabilities	$	18,669	$	18,686

Changes in short-term and long-term contract liabilities for the year ended December 31, 2024, were as follows:


	Contract Liabilities
Balance on January 1, 2024	18,686
Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied	(17)
Balance on December 31, 2024	$	18,669

The change in the Company’s contract liabilities for the year ended December 31, 2024, was primarily due to the deferred revenue related to the Huadong Agreement.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2024

Income Tax Disclosure [Abstract]

Schedule of Effective Income Tax Rate Reconciliation

A reconciliation of the U.S. statutory income tax rate to the Company’s effective tax rate is as follows (in thousands):


	December 31,
	2024			2023			2022
U.S. statutory tax benefit	$	(4,747)		$	(5,453)		$	(5,223)
Partnership income (federal) not subject to tax to the Company	891			1,200			1,241
Foreign withholding tax	79			—			158
State taxes (net of federal benefit)	(928)			(2)			28
Research and development tax credit	(373)			(273)			(172)
Other	190			(64)			40
Change in valuation allowance	4,988			4,592			4,128
Provision for income taxes	$	100		$	—		$	200
Effective income tax rate	(0.4)		%	0.0		%	(0.8)		%

Schedule of Net Deferred Tax Assets/(Liabilities)

Significant components of our net deferred tax assets/(liabilities) are as follows (in thousands):


	December 31,
	2024		2023
Deferred tax assets:
Net operating loss carryforwards	$	27,819	$	23,718
R&D Tax Credit carryforwards	2,491		2,215
Investment in partnerships	3,322		2,726
Charitable contributions	2		3
Capital loss carryforward	395		380
Total deferred tax assets	34,030		29,042
Valuation allowance	(34,030)		(29,042)
Net deferred tax assets	$	—	$	—

Segment Information - Additional Information (Details)

12 Months Ended

Dec. 31, 2024

USD ($)

Segment

Dec. 31, 2023

USD ($)

^[1]

Dec. 31, 2022

USD ($)

Segment Reporting Information [Line Items]

Number of reportable segment | Segment

Revenue

$ 1,017,000

$ 0

$ 2,018,000

^[1]

Reportable Segment

Segment Reporting Information [Line Items]

Revenue

$ 1,000,000.0

$ 2,000,000.0

[1]	(*) Adjusted retroactively for reverse stock split

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 2,757	$ 1,578	$ 1,272
Research and development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	742	425	406
General and administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 2,015	$ 1,153	$ 866

Property and Equipment

12 Months Ended

Dec. 31, 2024

Property, Plant and Equipment [Abstract]

Property and Equipment

Property and equipment consists of the following (in thousands):


	December 31,
	2024		2023
Leasehold improvements	$	406	$	406
Computers and hardware	69		69
Software	12		80
Furniture and office equipment	49		49
Total property and equipment	536		604
Less: accumulated depreciation and amortization	(508)		(487)
Property and equipment, net	$	28	$	117

Depreciation expense was $0.1 million for the years ended December 31, 2024, 2023 and 2022. The Company had fully depreciated disposals of $0.1 million for the year ended December 31, 2024.

Fair Value of Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2024

Fair Value Disclosures [Abstract]

Summarizes the Conclusions Reached Regarding Fair Value Measurements

The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2024, 2023 and 2022 (in thousands):


	Balance at December 31, 2024		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability, related party (1)(2)	$	57	$	—	$	—	$	57
Warrant liability(1)	$	43	$	—	$	—	$	43
Total	$	100	$	—	$	—	$	100


(1)			Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
(2)			CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.


	Balance at December 31, 2023		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Warrant liability, related party (1)	$	110	$	—	$	—	$	110
Total	$	110	$	—	$	—	$	110

_____________________________

(1)Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company's common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.


	Changes in Level 3 Instruments for the years ended December 31, 2024, 2023 and 2022
	Balance at January 1		Net Change in fair value included in earnings		Purchases / Issuance		Sales / Repurchases		Reclass		Balance at December 31, 2024
2024
Warrant liability, related party (1)(2)	$	110	$	150	$	—	$	—	$	(203)	$	57
Warrant liability(1)	—		(160)		—		—		203		43
Total	$	110	$	(10)	$	—	$	—	$	—	$	100

2023
Warrant liability, related party (1)	684		(574)		—		—				110
Total	$	684	$	(574)	$	—	$	—	$	—	$	110

2022
Warrant liability, related party (1)	1,262		(946)		368		—				684
Total	$	1,262	$	(946)	$	368	$	—	$	—	$	684


(1)			Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
(2)			CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.

Assumptions Used to Calculate Fair Value of Warrants

Fair value of the Letter Agreement Warrants was calculated as of their issuance date using the methods described in Note 18 using the following assumptions:


	December 5, 2017	July 30, 2018	December 11, 2018	September 26, 2019	December 23, 2019
Expected volatility	90.00%	95.29%	104.46%	110.35%	110.41%
Expected life of option, in years	7.0	7.0	7.0	7.0	7.0
Risk-free interest rate	2.80%	2.94%	2.77%	1.65%	1.84%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%

Significant inputs utilized in the valuation of the Letter Agreement Warrants were:


	December 31, 2024		December 31, 2023
	Range	Weighted Average	Range	Weighted Average
Expected volatility	88.01% - 116.31%	105.97%	79.96% - 89.61%	81.55%
Risk-free interest rate	4.17% - 4.25%	4.23%	4.01% - 4.87%	4.15%

The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of December 31, 2024, were:


	December 31, 2024		December 31, 2023
Expected volatility	96.5	%	82.1	%
Expected life of options in years	2.5		3.5
Risk-free interest rate	4.3	%	4.0	%
Expected dividend yield	—	%	—	%

Fair Value of Financial Instruments - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair value equity transfers in and out of level 3 instruments	$ 0	$ 0	$ 0

Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Contract with Customer, Contract Asset, Contract Liability, and Receivable

Contract Liabilities


	December 31, 2024		December 31, 2023
Current portion of contract liabilities	$	—	$	17
Contract liabilities, net of current portion	18,669		18,669
Total contract liabilities	$	18,669	$	18,686

Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes

Changes in short-term and long-term contract liabilities for the year ended December 31, 2024, were as follows:


	Contract Liabilities
Balance on January 1, 2024	18,686
Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied	(17)
Balance on December 31, 2024	$	18,669

Stockholders’ Equity (Deficit) - Assumptions Used to Calculate Fair Value of Warrants (Detail) - Letter Agreement Warrants	Dec. 23, 2019 yr	Sep. 26, 2019 yr	Dec. 11, 2018 yr	Jul. 30, 2018 yr	Dec. 05, 2017 yr
Expected volatility
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	110.41	110.35	104.46	95.29	90.00
Expected life of option, in years
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	7.0	7.0	7.0	7.0	7.0
Risk-free interest rate
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	1.84	1.65	2.77	2.94	2.80
Expected dividend yield
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Measurement input	0.0000	0.0000	0.0000	0.0000	0.0000

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 36,746	$ 9,446
Accounts receivable, net	62	102
Prepaid expenses and other current assets	1,220	1,044
Current deposits	85	65
Total current assets	38,113	10,657
Property and equipment, net	28	117
Operating lease right-of-use assets	125	244
Total assets	38,266	11,018
Current liabilities:
Accounts payable and accrued expenses	5,027	10,242
Current portion of operating lease liabilities	169	169
Current portion of contract liabilities	0	17
Current portion of notes payable	0	191
Total current liabilities	5,196	10,619
Contract liabilities, net of current portion	18,669	18,669
Operating lease liabilities, net of current portion	0	169
Total liabilities	23,965	29,567
Commitments and contingencies
Redeemable noncontrolling interest	0	6,131
Stockholders’ equity (deficit):
Additional paid-in capital	311,885	256,335
Accumulated deficit	(299,718)	(281,042)
Total stockholders’ equity (deficit) attributable to vTv Therapeutics Inc.	12,199	(24,680)
Noncontrolling interest	2,102	0
Total stockholders’ equity (deficit)	14,301	(24,680)
Total liabilities, redeemable noncontrolling interest and stockholders’ equity (deficit)	38,266	11,018
Related Party
Current liabilities:
Warrant liability	57	110
Nonrelated Party
Current liabilities:
Warrant liability	43	0
Class A Common Stock
Stockholders’ equity (deficit):
Common stock value	$ 26	$ 21
Common stock, shares outstanding (in shares)	2,084,973	2,612,257
Class B Common Stock
Stockholders’ equity (deficit):
Common stock value	$ 6	$ 6
Common stock, shares outstanding (in shares)	577,349	577,349

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.

Concentration of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions. The balance of the cash account frequently exceeds insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.

Two collaboration partners represented 100% of the revenue earned during the year ended December 31, 2024 and was attributable from the satisfaction of a development milestone from the Newsoara License Agreement and the satisfaction of a performance obligation from the First Huadong Amendment (as defined herein). One collaboration partner represented 100% of the revenue during the year ended December 31, 2022. The Company did not have any revenue during the year ended December 31, 2023.

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Collaboration Revenue and Accounts Receivable

The majority of the Company’s collaboration revenue and accounts receivable relates to its agreements to license certain of its potential drug products for development. See Note 3 for further discussion of the Company’s collaboration agreements.

Accounts receivable are stated at net realizable value. On a periodic basis, the Company evaluates its accounts receivable and establishes an allowance based on its history of collections and write-offs and the current status of all receivables.

Property and Equipment and other Long-lived Assets

The Company records property and equipment at cost less accumulated depreciation. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is determined on a straight-line basis over the estimated useful lives of the assets, which generally range from three to seven years. Leasehold improvements are depreciated over the shorter of the useful life of the asset or the term of the

related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.

The estimated useful lives of property and equipment are as follows:


Asset Category			Useful Life (in years)

Computers and hardware			3-5
Furniture and office equipment			3-7
Software			3
Leasehold improvements			Shorter of useful life or remaining term of lease

The Company periodically assesses its property and equipment and other long-lived assets for impairment in accordance with the relevant accounting guidance. No such charges were recognized during the years ended December 31, 2024, 2023 or 2022. There were no assets held for sale at December 31, 2024 or 2023.

Investments

Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Consolidated Statements of Operations.

Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.

As of December 31, 2024, the Company has no investments.

Revenue Recognition

The Company uses the revenue recognition guidance established by ASC 606, “Revenue From Contracts With Customers” (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.

The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.

The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.

Fair Value of Financial Instruments

The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods

subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows:

•Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

•Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

•Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Research and Development

Major components of research and development costs include cash compensation to employees, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.

The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its consolidated financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.

The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Consolidated Statements of Operations as the Company receives the related goods or services.

Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations.

Income Taxes

From its formation on August 1, 2015, vTv Therapeutics Inc. has been subject to corporate level income taxes. Prior to July 30, 2015, the Company’s predecessor entities were taxed as partnerships and all their income and deductions flowed through and were subject to tax at the partner level.

vTv Therapeutics Inc. is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC.

The Company’s income tax expense, deferred tax assets and liabilities and reserves for unrecognized tax benefits reflect management’s best assessment of estimated future taxes to be paid. The Company is subject to income taxes in both the United States and various state jurisdictions. Significant judgments and estimates are required in determining the consolidated income tax expense.

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events included in the consolidated financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of differences between the consolidated financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period in which the enactment date occurs.

The Company recognizes deferred tax assets to the extent it believes these assets are more-likely-than-not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including

future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.

The Company records uncertain tax positions on the basis of a two-step process in which (1) it determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions meeting the more-likely-than-not recognition threshold, it recognizes the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company’s Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented.

Noncontrolling Interest

Non-controlling interests have been recorded to reflect the various holders of non-voting interests in vTv LLC, representing an 18.1% economic interest. This non-controlling interest is presented as a separate component of equity in the consolidated balance sheets and as a loss in the consolidated statements of operations.

Prior to February 27, 2024, the Company recorded the noncontrolling interest represented by the vTv Units and the Class B common stock at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. See discussion and additional detail of the noncontrolling interest at Note 12.

Segment and Geographic Information

Operating segments are defined as an enterprise’s components (business activities from which it earns revenue and incurs expenses) for which discrete financial information is (1) available; and (2) is regularly reviewed by the chief operating decision maker (“CODM”) in deciding how to allocate resources and in assessing performance. The Company’s CODM is its President and Chief Executive Officer. All of the Company's principal operations, assets, and decision-making functions are based in the U.S., and as a result, all of our financial information is derived from domestic sources. The Company’s business operates in one reportable segment comprised of one operating segment.

Leases

The Company determines if an arrangement is a lease at inception. Balances recognized related to operating leases are included in operating lease right-of-use assets and operating lease liabilities in the Consolidated Balance Sheets. Operating lease right-of-use assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The operating lease right-of-use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has elected a practical expedient to not separate its lease and non-lease components and instead account for them as a single lease component.

Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred.

Share-Based Compensation

Compensation expense for share-based compensation awards issued is based on the fair value of the award at the date of grant, and compensation expense is recognized for those awards earned over the service period. The grant date fair value of stock option awards is estimated using the Black-Scholes option pricing formula. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period commensurate with the estimated expected term of the Company’s stock options offering period which is derived from historical experience. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. Due to a lack of historical exercise data, the Company estimates the expected life of its outstanding stock options using the simplified method specified under Staff Accounting Bulletin Topic 14.D.2.

In the event the participant’s employment by or engagement with (as a director or otherwise) the Company terminates before exercise of the options granted, the stock options granted to the participant shall immediately expire and all rights to purchase shares there under shall immediately cease and expire and be of no further force or effect, other than applicable

exercise rights for vested shares that may extend past the termination date as provided for in the participant’s applicable option award agreement.

The fair value of restricted stock units (“RSU”) grants is based on the market value of the Class A common stock on the date of grant. The Company also estimates the amount of share-based awards that are expected to be forfeited based on historical employee turnover rates.

Comprehensive Income

The Company does not have any components of other comprehensive income recorded within its Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Consolidated Financial Statements.

Accounting Pronouncements Adopted During the Current Year and Recently Issues Accounting Pronouncements Not Yet Adopted

Accounting Pronouncements Adopted During the Current Year

Segment Reporting: In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): “Improvements to Reportable Segment Disclosures” (ASU 2023-07). The ASU expands public entities' segment disclosures by requiring disclosures of significant segment expenses that are regularly provided to the CODM and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. For public entities, the provisions within ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and for interim periods of fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 effective December 31, 2024, on a retrospective basis. The adoption of 2023-07 did not change the way that the Company identifies its reportable segments and, as a result, did not have a material impact on the Company’s segment-related disclosures. Refer to Note 14 for further information on the Company's reportable segment.

Recently Issued Accounting Pronouncements Not Yet Adopted

Income Taxes: In December 2023, the FASB issued ASU 2023-09: “Improvements to Income Tax Disclosures” (“ASU 2023-09”). The ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in the ASU address investor requests for enhanced income tax information primarily through changes to the rate reconciliation and income taxes paid information. ASU 2023-09 will be effective for us in the annual period beginning January 1, 2025, though early adoption is permitted. The Company is currently evaluating the presentational effect that ASU 2023-09 will have on the Company's Consolidated Financial Statements and disclosures, but we expect considerable changes to our income tax disclosures.

Disaggregation of Income Statement Expenses: In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures: Disaggregation of Income Statement Expenses”. This guidance requires disclosures about significant expense categories, including but not limited to, inventory purchases, employee compensation, depreciation, amortization, and selling expenses. This amendment is effective for our annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. We are currently assessing the impact of this guidance on our disclosures.

Noncontrolling Interest

12 Months Ended

Dec. 31, 2024

Noncontrolling Interest [Abstract]

Noncontrolling Interest

The Company is subject to the Exchange Agreement with respect to the vTv Units representing the outstanding 18.1% noncontrolling interest in vTv LLC (see Note 1). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair

market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20 day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.

On February 27, 2024, in connection with the Private Placement financing, the Investor Rights Agreement altered M&F TTP Holdings Two LLC (“M&F”) governance rights such that directors designated by M&F no longer comprise a majority of the Company’s Board of Directors (see Note 13). The redeemable noncontrolling interest redemption feature to exchange vTv Units for cash rather than shares of Class A common stock is a contingent event that is now within control of the Company through the Company’s independent Board of Directors. As a result, $5.3 million representing the fair value of redeemable noncontrolling interest on February 27, 2024, was reclassified from temporary equity in the mezzanine section of the Consolidated Balance Sheets to noncontrolling interest as a component of permanent equity.

Prior to February 27, 2024, the Company recorded redeemable noncontrolling interest at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At December 31, 2023, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $6.1 million.

Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:


	December 31,
	2024		2023		2022
Net loss attributable to vTv Therapeutics Inc. common shareholders	$	(18,462)	$	(20,250)	$	(19,164)
Decrease in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances	(7,592)		—		(1,061)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest	$	(26,054)	$	(20,250)	$	(20,225)

Stockholders’ Equity (Deficit)

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

Stockholders’ Equity (Deficit)

Amendment to Certificate of Incorporation

On July 29, 2015, the Company amended and restated its certificate of incorporation to authorize 100,000,000 shares of Class A common stock, 100,000,000 shares of Class B common stock and 50,000,000 shares of preferred stock, par value $0.01 per share.

On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.

On November 20, 2023, the Company filed an amendment to its Amended and Restated Certificate of Incorporation as amended, to effect a reverse stock split at a ratio of 1-for-40 (the "Reverse Stock Split"). Pursuant to the Reverse Stock Split, every 40 shares of the Company’s Class A common stock was combined into one issued and outstanding share of Class A Common Stock and every 40 shares of the Company’s Class B common stock was combined into one issued and outstanding share of Class B Common Stock. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remained at 200,000,000 and 100,000,000 respectively and did not change the par value of the common stock, which remained at $0.01 per share. The Reverse Stock Split did not have any effect on the number of authorized shares of the Company’s preferred stock, par value of $0.01 per share, which would remain at 50,000,000 shares. Currently no shares of preferred stock are outstanding.

Holders of Class A common stock and Class B common stock are entitled to one vote for each share held on all matters submitted to stockholders for their vote or approval. The holders of Class A common stock and Class B common stock will vote together as a single class on all matters submitted to stockholders for their vote or approval, except with respect to the amendment of certain provisions of the Company’s amended and restated certificate of incorporation that would alter or change the powers, preferences or special rights of the Class B common stock so as to affect them adversely, which amendments must be approved by a majority of the votes entitled to be cast by the holders of the shares affected by the amendment, voting as a separate class, or as otherwise required by applicable law. The voting power of the outstanding Class B common stock (expressed as a percentage of the total voting power of all common stock) will be equal to the percentage of vTv Units not held by the Company. Holders of Class B common stock are not entitled to receive dividends and will not be entitled to receive any distributions upon the liquidation, dissolution or winding up of the Company.

Common Stock and Pre-funded Warrants

In February 2024, the Company entered into a Securities Purchase Agreement with certain Private Placement Investors, pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (i) an aggregate of 464,377 shares of our Class A common stock, at a purchase price of $11.81 per share and (ii) issued pre-funded warrants to purchase an aggregate of 3,853,997 shares of the Company’s Class A common stock at a price of $11.80 per pre-funded warrant. The pre-funded warrants were immediately exercisable, have an exercise price of $0.01 and may be exercised at any time after the date of issuance. A holder of pre-funded warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise. A holder of the pre-funded warrants may increase or decrease this percentage not in excess of 19.99% by providing at least 61 days’ prior notice to the Company. As of December 31, 2024, there were pre-funded warrants to purchase an aggregate of 3,970,587 shares of the Company’s common stock that remained available for exercise.

The pre-funded warrants were classified as a component of permanent equity in the Company's Consolidated Balance Sheet as they are freestanding financial instruments that are immediately exercisable, do not embody an obligation for the Company to repurchase its own shares and permit the holders to receive a fixed number of shares of common stock upon exercise. All of the shares underlying the pre-funded warrants have been included in the weighted-average number of shares of common stock used to calculate net loss per share attributable to common stockholders because the shares may be issued for little or no consideration, are fully vested and are exercisable after the original issuance date of the pre-funded warrants.

On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants.

G42 Investments Transaction

On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 259,657 shares of the Company's Class A common stock, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the "G42 Promissory Note"). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income (expense) net, in the Company’s Consolidated Statements of Operations.

CinPax and CinRx Transaction

On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax, LLC ("CinPax") and CinRx-Pharma, LLC ("CinRx"), pursuant to which the Company agreed to sell to CinPax 103,864 shares of the Company’s Class A common stock, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022.

The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 30,000 shares of common stock at an initial exercise of price of approximately $28.80 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 18)

The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, cadisegliatin (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.

Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time.

The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par. The Company, CinPax and CinRx subsequently amended the CinRx Purchase Agreement on February 27, 2024, in connection with the Private Placement. The CinRx Purchase Agreement provides CinPax the right for two years following the Closing to designate a board observer, which has been subsequently approved by the Company’s board.

ATM Offering

On February 28, 2024, we entered into a sales agreement (the “TD Cowen Sales Agreement”) with Cowen and Company, LLC (“TD Cowen”), pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements.

During the year ended December 31, 2024, the Company sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million.

Letter Agreement Warrants

The Company previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock. Certain terms of each of these Letter Agreements are set forth in Note 13.

The Letter Agreement Warrants were recorded as warrant liability, related party within the Company’s Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. During the years ended December 31, 2024, 2023 and 2022 the Company recognized $(0.2) million, $0.6 million and $0.9 million respectively in the Consolidated Statement of Operations, related to the change in fair value in related party warrants of which $(0.2) million, $0.3 million, and $0.9 million, respectively, were related to the Letter Agreement Warrants. These amounts were recognized as a component of other (expense) income - related party in the Consolidated Statements of Operations.

Fair value of the Letter Agreement Warrants was calculated as of their issuance date using the methods described in Note 18 using the following assumptions:


	December 5, 2017	July 30, 2018	December 11, 2018	September 26, 2019	December 23, 2019
Expected volatility	90.00%	95.29%	104.46%	110.35%	110.41%
Expected life of option, in years	7.0	7.0	7.0	7.0	7.0
Risk-free interest rate	2.80%	2.94%	2.77%	1.65%	1.84%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%

The warrants issued on December 5, 2017 expired on December 5, 2024.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

+ Details

Description of Business, Basis of Presentation and Going Concern - Additional Information (Detail) $ / shares in Units, $ in Thousands					12 Months Ended
	Sep. 17, 2024 USD ($) shares	Feb. 27, 2024 USD ($) $ / shares shares	Nov. 20, 2023 $ / shares shares	Nov. 14, 2023 $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Mar. 05, 2024 shares	Feb. 28, 2024 USD ($) Rate	Dec. 31, 2023 USD ($) $ / shares shares	May 04, 2021 shares	Dec. 31, 2020 shares	Jul. 29, 2015 $ / shares shares
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Cash and cash equivalents \| $					$ 36,746			$ 9,446
Common stock par value (usd per share) \| $ / shares			$ 0.01
Preferred stock par value (usd per share) \| $ / shares			$ 0.01								$ 0.01
Preferred stock, shares authorized (in shares)			50,000,000								50,000,000
Preferred stock, shares outstanding (in shares)			0
Retained earnings (accumulated deficit) \| $					(299,718)			$ (281,042)
Percent of public float							33.30%
Parent Company
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Cash and cash equivalents \| $					$ 29,200
Private Placement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Proceeds from issuance of private placement \| $		$ 51,000
Private placement, shares (in shares)						116,493
Private placement pre-funded warrants, shares (in shares)						116,590
Private Placement \| Private Placement Pre-Funded Warrants
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Exercise price of warrants (usd per share) \| $ / shares		$ 0.01
TD Cowen Sales Agreement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Entity public float, threshold \| $							$ 75,000
Commission percent \| Rate							3.00%
Class A Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock par value (usd per share) \| $ / shares				$ 0.01	$ 0.01			$ 0.01			$ 0.01
Stock split, conversion ratio			0.025	0.025
Common stock, shares authorized (in shares)			200,000,000	91,835,204	200,000,000			200,000,000	200,000,000	100,000,000	100,000,000
Shares sold (in shares)	179,400
Aggregate gross purchase price \| $	$ 2,500
Class A Common Stock \| Private Placement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Shares sold (in shares)		464,377
Share price (usd per share) \| $ / shares		$ 11.81
Class A Common Stock \| Private Placement \| Private Placement Pre-Funded Warrants
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Share price (usd per share) \| $ / shares		$ 11.80
Warrants to purchase shares of common stock (in shares)		3,853,997			3,970,587
Class A Common Stock \| TD Cowen Sales Agreement
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Shares sold (in shares)					179,400
Aggregate offering price \| $							$ 50,000
Aggregate gross purchase price \| $					$ 2,500
Class B Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock par value (usd per share) \| $ / shares				$ 0.01	$ 0.01			$ 0.01			$ 0.01
Stock split, conversion ratio			0.025
Common stock, shares authorized (in shares)			100,000,000		100,000,000			100,000,000			100,000,000
vTv Therapeutics LLC
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC					18.10%
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC					81.90%
vTv Therapeutics LLC \| Class B Common Stock
Organization Consolidation And Presentation Of Financial Statements [Line Items]
Common stock par value (usd per share) \| $ / shares					$ 0.01

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Noncontrolling Interest - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Feb. 27, 2024	Dec. 31, 2023
Noncontrolling Interest [Line Items]
Redeemable noncontrolling interest, equity, fair value		$ 5.3
Redemption amount of noncontrolling interest			$ 6.1
Class A Common Stock
Noncontrolling Interest [Line Items]
Number of days used to determine exchange value based on weighted average price of Class A common stock	20 days
Class A Common Stock \| Exchange of Redeemable Non controlling Interest To Class A Common Stock
Noncontrolling Interest [Line Items]
Stock conversion ratio	1
vTv Therapeutics LLC
Noncontrolling Interest [Line Items]
Noncontrolling interest ownership percentage	18.10%

Related-Party Transactions

12 Months Ended

Dec. 31, 2024

Related-Party Transactions

MacAndrews & Forbes Incorporated

As of December 31, 2024, MacAndrews directly or indirectly controlled 577,108 shares of Class B common stock and directly or indirectly held 912,982 shares of the Company’s Class A common stock. As a result, as of December 31, 2024 MacAndrews’ holdings represented approximately 46.7% of the combined voting power of the Company’s outstanding common stock.

The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:

Letter Agreements

The Company previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued the Letter Agreement Warrants to purchase additional shares of the Company’s Class A common stock.

Certain terms of these Letter Agreements are set forth in the tables below:


	December 5, 2017 Letter Agreement		July 30, 2018 Letter Agreement		December 11, 2018 Letter Agreement		March 18, 2019 Letter Agreement		September 26, 2019 Letter Agreement		December 23, 2019 Letter Agreement
Aggregate dollar value to be sold under agreement	$10.0 million		$10.0 million		$10.0 million		$9.0 million		$10.0 million		$10.0 million
Specified purchase price per share	$	175.20	$	53.20	$	73.60	$	66.00	$	58.40	$	64.00
Expiration date of letter agreement	December 5, 2018		July 30, 2019		December 11, 2019		March 18, 2020		September 26, 2020		December 23, 2020
Shares available to be issued under related warrants	4,956		12,966		8,513		—		10,024		9,136
Exercise price of related warrants	$	201.60	$	61.20	$	84.80	$	—	$	67.20	$	73.60
Expiration date of related warrants	December 5, 2024		July 30, 2025		December 11, 2025				September 26, 2026		December 23, 2026
Total shares issued as of December 31, 2024	57,077		187,969		135,869		136,363		171,232		156,250
Remaining shares to be issued as of December 31, 2024	—		—		—		—		—		—

Each of the December 5, 2017 and July 30, 2018 Letter Agreements resulted in a deemed capital contribution to the Company as the fair value of the financial instrument received by the Company exceeded the fair value of those financial instruments issued to MacAndrews. The December 11, 2018, March 18, 2019, September 26, 2019, and December 23, 2019 Letter Agreements resulted in a deemed distribution to MacAndrews as the fair value of the financial instruments issued to MacAndrews exceeded the fair value of the financial instrument received by the Company.

Exchange Agreement

Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company's Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of December 31, 2024, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.

Tax Receivable Agreement

The Company and MacAndrews are party to a tax receivable agreement (the "Tax Receivable Agreement"), which provides for the payment by the Company, M&F TTP Holdings Two LLC, as successor in interest to vTv Therapeutics Holdings (“M&F”) and M&F TTP Holdings LLC provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability nor has it made any payments pursuant to the Tax Receivable Agreement as of December 31, 2024.

Investor Rights Agreement

The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors. The Investor Rights Agreement was amended on February 27, 2024 to alter M&F

governance rights that now entitles M&F the right to designate two members of our Board of Directors, and as part of the Private Placement, the Private Placement Investors have rights to designate three members of our Board of Directors, making it more difficult for a third party to acquire control of our Board. The agreement with the Private Placement Investors also provides that five of our directors must approve certain actions including any acquisition by a third party, which makes it more difficult for our Board of Directors to approve such a transaction.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

+ Details

Stockholders’ Equity (Deficit) (Tables)

12 Months Ended

Dec. 31, 2024

Equity [Abstract]

Assumptions Used to Calculate Fair Value of Warrants

Fair value of the Letter Agreement Warrants was calculated as of their issuance date using the methods described in Note 18 using the following assumptions:


	December 5, 2017	July 30, 2018	December 11, 2018	September 26, 2019	December 23, 2019
Expected volatility	90.00%	95.29%	104.46%	110.35%	110.41%
Expected life of option, in years	7.0	7.0	7.0	7.0	7.0
Risk-free interest rate	2.80%	2.94%	2.77%	1.65%	1.84%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%	0.00%

Significant inputs utilized in the valuation of the Letter Agreement Warrants were:


	December 31, 2024		December 31, 2023
	Range	Weighted Average	Range	Weighted Average
Expected volatility	88.01% - 116.31%	105.97%	79.96% - 89.61%	81.55%
Risk-free interest rate	4.17% - 4.25%	4.23%	4.01% - 4.87%	4.15%


	December 31, 2024		December 31, 2023
Expected volatility	96.5	%	82.1	%
Expected life of options in years	2.5		3.5
Risk-free interest rate	4.3	%	4.0	%
Expected dividend yield	—	%	—	%

Accounts Payable and Accrued Expenses

12 Months Ended

Dec. 31, 2024

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following (in thousands):


	December 31,
	2024		2023
Accounts payable	$	939	$	4,075
Accrued development costs	2,263		4,401
Accrued compensation and related costs	1,509		1,466
Accrued other	316		300
Total	$	5,027	$	10,242

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Use of Estimates

Concentration of Credit Risk

Cash and Cash Equivalents

The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.

Collaboration Revenue and Accounts Receivable

Property and Equipment and other Long-lived Assets

The estimated useful lives of property and equipment are as follows:


Asset Category			Useful Life (in years)

Computers and hardware			3-5
Furniture and office equipment			3-7
Software			3
Leasehold improvements			Shorter of useful life or remaining term of lease

Investments

As of December 31, 2024, the Company has no investments.

Revenue Recognition

Fair Value of Financial Instruments

•Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets;

•Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and

•Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions.

Research and Development

Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.

Patent Costs

Patent costs, including related legal costs, are expensed as incurred and recorded within general and administrative operating expenses on the Consolidated Statements of Operations.

Income Taxes

vTv Therapeutics Inc. is required to recognize deferred tax assets and liabilities for the difference between the financial reporting and tax basis of its investment in vTv LLC.

future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent results of operations.

Noncontrolling Interest

Segment and Geographic Information

Leases

Share-Based Compensation

exercise rights for vested shares that may extend past the termination date as provided for in the participant’s applicable option award agreement.

Comprehensive Income

Accounting Pronouncements Adopted During the Current Year

Recently Issued Accounting Pronouncements Not Yet Adopted

Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Current portion of contract liabilities	$ 0	$ 17
Contract liabilities, net of current portion	18,669	18,669
Total contract liabilities	$ 18,669	$ 18,686

Description of Business, Basis of Presentation and Going Concern	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Description of Business, Basis of Presentation and Going Concern	Description of Business, Basis of Presentation and Going Concern Description of Business vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic diseases to minimize their long-term complications through end-organ protection. Principles of Consolidation vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Consolidated Financial Statements. The assets and liabilities of vTv LLC represent substantially all of the Company's consolidated assets and liabilities with the exception of the Warrants and $29.2 million of cash and cash equivalents. Various holders own non-voting interests in vTv LLC, representing a 18.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 81.9% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional non-voting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 per share (the “Class B common stock”)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 13). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). vTv Therapeutics Inc. entered into a common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”), the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). In addition vTv Therapeutics Inc also entered into a Securities Purchase Agreement with Private Placement Investors and the sales agreement with Cowen and Company, LLC (“TD Cowen”) (“TD Cowen Sales Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss. Reverse Stock Split On November 14, 2023, the Board of Directors of the Company approved a reverse stock split at a ratio of 1-for-40, such that every 40 shares of the Company’s Class A common stock, par value $0.01 per share (the “Class A common stock”), would be combined into one issued and outstanding share of Class A common stock, and every 40 shares of the Company’s Class B common stock, par value $0.01 per share (the “Class B common stock”), would be combined into one issued and outstanding share of Class B Common Stock (together, the “Reverse Stock Split”). On November 20, 2023, the Company filed a Certificate of Amendment to the Company’s amended and restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware, which effected a reverse stock split of our Class A common stock and Class B common stock at a ratio of 1-for-40. No fractional shares were issued in connection with the Reverse Stock Split. Any fractional shares of Class A common stock and Class B common stock to which a stockholder was entitled resulting from the Reverse Stock Split were rounded up to the nearest whole share. The Class A common stock began trading on a reverse split-adjusted basis on the Nasdaq on November 21, 2023. The Company’s Class A common stock will continue trading under the symbol “VTVT,” and the new CUSIP number for the Class A common stock following the Reverse Stock Split is 91835204. The Reverse Stock Split did not reduce the number of authorized shares of Class A and Class B common stock, which remains at 200,000,000 and 100,000,000, respectively and did not change the par value of the common stock, which remains at $0.01 per share. The Company retroactively adjusted its consolidated financial statements to reflect the Reverse Stock Split. All issued and outstanding common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this Reverse Stock Split for all periods presented. In addition, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the exercise and/or vesting of all warrants to purchase shares of common stock. A proportionate adjustment was also made to the number of shares reserved for issuance pursuant to the Company’s equity incentive compensation plans to reflect the Reverse Stock Split. The common stock and additional paid-in-capital line items contained in the consolidated financial statements were adjusted to account for the Reverse Stock Split for all periods presented. The reverse stock split did not have any effect on the number of authorized shares of the Company’s preferred stock, par value of $0.01 per share, remains at 50,000,000 shares. Currently no shares of preferred stock are outstanding. Going Concern and Liquidity To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through December 31, 2024, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of December 31, 2024, the Company had an accumulated deficit of $299.7 million and has generated net losses in each year of its existence. As of December 31, 2024, the Company's liquidity sources included cash and cash equivalents of $36.7 million. To meet our future funding requirements into the first quarter of 2026, including funding the ongoing and future clinical trials of cadisegliatin (TTP399), we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs. On February 27, 2024, we entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Private Placement Investors”), pursuant to which we agreed to issue and sell to the Private Placement Investors in a private placement (the “Private Placement”) (i) an aggregate of 464,377 shares (the “Private Placement Shares”) of our Class A common stock, at a purchase price of $11.81 per share, and (ii) pre-funded warrants (the “Private Placement Pre-Funded Warrants”) to purchase up to an aggregate of 3,853,997 shares of our Class A common stock (the “Private Placement Warrant Shares”) at a purchase price of $11.80 per Private Placement Pre-Funded Warrant (representing the $11.81 per Private Placement Share purchase price less the exercise price of $0.01 per Private Placement Warrant Share). We received aggregate gross proceeds from the Private Placement of approximately $51.0 million, before deducting offering expenses payable by us. The Private Placement Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire. On March 5, 2024, the Company entered into a letter agreement with the Private Placement Investors pursuant to which the Private Placement Investors agreed to exchange an aggregate of 116,493 Private Placement Shares for an aggregate of 116,590 Private Placement Pre-Funded Warrants. On February 28, 2024, we entered into the TD Cowen Sales Agreement, pursuant to which we may offer and sell, from time to time, through or to TD Cowen, as sales agent or principal, shares of our Class A common stock, having an aggregate offering price of up to $50.0 million (the “TD Cowen ATM Offering”). Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities registered on the registration statement relating to the TD Cowen ATM Offering with a value exceeding more than one-third of our public float in any 12-month period so long as our public float remains below $75.0 million. Under the terms of the TD Cowen Sales Agreement, we will pay TD Cowen a commission of 3.0% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. On September 17, 2024, the Company sold 179,400 shares of Class A common stock under the TD Cowen ATM Offering for net proceeds of $2.5 million. If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition. As such, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2024

Accounting Policies [Abstract]

Summary of Estimated Useful Lives of Property and Equipment

The estimated useful lives of property and equipment are as follows:


Asset Category			Useful Life (in years)

Computers and hardware			3-5
Furniture and office equipment			3-7
Software			3
Leasehold improvements			Shorter of useful life or remaining term of lease

Net Loss per Share

12 Months Ended

Dec. 31, 2024

Earnings Per Share [Abstract]

Net Loss per Share

Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):


	Year Ended December 31,
	2024		2023(*)		2022(*)
Numerator:
Net loss	$	(22,705)	$	(25,966)	$	(25,073)
Less: Net loss attributable to noncontrolling interests	(4,243)		(5,716)		(5,909)
Net loss attributable to vTv Therapeutics Inc.	(18,462)		(20,250)		(19,164)

Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted	$	(18,462)	$	(20,250)	$	(19,164)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (1)	5,771,052		2,084,973		1,919,788
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted	$	(3.20)	$	(9.71)	$	(9.98)
(*) Adjusted retroactively for reverse stock split, see Note 1


			(1)			The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the year ended December 31, 2024.

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:


	Year Ended December 31,
	2024	2023(*)	2022(*)
Class B common stock (1) (*)	577,349	577,349	577,349
Common stock options granted under the Plan (*)	705,593	249,247	208,586
Common stock warrants (*)	70,639	76,545	80,359
Total (*)	1,353,581	903,141	866,294
(*) Adjusted retroactively for reverse stock split, see Note 1

________________________________________________

(1)Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has

not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.

Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment

Significant segment expenses are included in the table below and represent direct and indirect research and development expenses by project for the years ended December 31, 2024, 2023 and 2022 were as follows (in thousands):


	Years Ended December 31,
	2024		2023		2022
Direct research and development expense:
Cadisegliatin	6,026		10,182		9,611
Other projects*	490		676		563
Indirect research and development expense†	5,030		2,737		2,183
Total research and development expense	$	11,546	$	13,595	$	12,357


*			Includes HPP737 and azeliragon
†			Includes share-based compensation

Employee Benefit Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Retirement Benefits [Abstract]
Percentage of employer contribution	50.00%
Maximum annual contribution per employee	6.00%
Contributions made by employer	$ 0.1	$ 0.1

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Dec. 31, 2024	Mar. 20, 2025	Jun. 30, 2024
Document Information [Line Items]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-37524
Entity Registrant Name	vTv Therapeutics Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-3916571
Entity Address, Address Line One	3980 Premier Dr
Entity Address, Address Line Two	Suite 310
Entity Address, City or Town	High Point
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27265
City Area Code	336
Local Phone Number	841-0300
Title of 12(b) Security	Class A Common Stock, par value $0.01 per share
Trading Symbol	VTVT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 23,162,697
Documents Incorporated by Reference	Portions of the registrant’s Definitive Proxy Statement relating to its 2025 Annual Meeting of Stockholders to be filed within 120 days after December 31, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.
Entity Central Index Key	0001641489
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Amendment Flag	false
Class A Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		2,612,257
Class B Common Stock
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		577,349

Related-Party Transactions - Summary of Terms of Letter Agreements (Detail) - MacAndrews & Forbes Incorporated - Class A Common Stock - USD ($) $ / shares in Units, $ in Millions	Dec. 23, 2019	Sep. 26, 2019	Mar. 18, 2019	Dec. 11, 2018	Jul. 30, 2018	Dec. 05, 2017
2017 Letter Agreement
Class Of Warrant Or Right [Line Items]
Aggregate dollar value to be sold under agreement						$ 10.0
Specified purchase price per share (usd per share)						$ 175.20
Shares available to be issued under related warrants (in shares)						4,956
Exercise price of related warrants (usd per share)						$ 201.60
Total shares issued as of December 31, 2024 (in shares)						57,077
2018 Letter Agreement
Class Of Warrant Or Right [Line Items]
Aggregate dollar value to be sold under agreement				$ 10.0	$ 10.0
Specified purchase price per share (usd per share)				$ 73.60	$ 53.20
Shares available to be issued under related warrants (in shares)				8,513	12,966
Exercise price of related warrants (usd per share)				$ 84.80	$ 61.20
Total shares issued as of December 31, 2024 (in shares)				135,869	187,969
2019 Letter Agreement
Class Of Warrant Or Right [Line Items]
Aggregate dollar value to be sold under agreement	$ 10.0	$ 10.0	$ 9.0
Specified purchase price per share (usd per share)	$ 64.00	$ 58.40	$ 66.00
Shares available to be issued under related warrants (in shares)	9,136	10,024
Exercise price of related warrants (usd per share)	$ 73.60	$ 67.20
Total shares issued as of December 31, 2024 (in shares)	156,250	171,232	136,363

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2024

Prepaid Expense and Other Assets, Current [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	December 31,
	2024		2023
Prepaid insurance	$	577	$	680


Prepaid - other	643		364
Total	$	1,220	$	1,044

Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Dilutive Net Loss per Share (Detail) - shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)	1,353,581	903,141	866,294
Class B Common Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)	577,349	577,349	577,349
Common stock options granted under the Plan
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)	705,593	249,247	208,586
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)	70,639	76,545	80,359

Share-Based Compensation - Additional Information (Detail) - USD ($)			12 Months Ended
	Feb. 27, 2024	Feb. 23, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-qualified stock option awards vesting period			4 years	4 years	4 years
Non-qualified stock option awards expiration term			10 years	10 years	10 years
Compensation expense related to share-based awards			$ 2,757,000	$ 1,578,000	$ 1,272,000
Tax benefit related to stock option awards			0	0
Stock options vested, fair value			2,900,000	$ 2,200,000	$ 1,500,000
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-qualified stock option awards vesting period	3 years
Unrecognized compensation cost related to non-vested share-based compensation arrangements			$ 4,700,000
Weighted average period to recognize unrecognized share-based compensation cost			2 years 3 months 18 days
Weighted average grant date fair value of options granted (usd per share)			$ 14.76	$ 24.78	$ 27.75
Share-based compensation arrangement by share-based payment award, modified common stock (in shares)		14,340
Share-based compensation arrangement by share-based payment award, accelerated vesting, number (in shares)		7,590
Share-based payment arrangement, expense reduction, amount			$ 100,000

Property and Equipment - Summary of Property and Equipment (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]
Total property and equipment	$ 536	$ 604
Less: accumulated depreciation and amortization	(508)	(487)
Property and equipment, net	28	117
Leasehold improvements
Property Plant And Equipment [Line Items]
Total property and equipment	406	406
Computers and hardware
Property Plant And Equipment [Line Items]
Total property and equipment	69	69
Software
Property Plant And Equipment [Line Items]
Total property and equipment	12	80
Furniture and office equipment
Property Plant And Equipment [Line Items]
Total property and equipment	$ 49	$ 49

Audit Information	12 Months Ended
Audit Information	Dec. 31, 2024
Audit Information [Abstract]
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	Raleigh, North Carolina

Fair Value of Financial Instruments

12 Months Ended

Dec. 31, 2024

Fair Value Disclosures [Abstract]

Fair Value of Financial Instruments

The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments. The following table summarizes the conclusions reached regarding fair value measurements as of December 31, 2024, 2023 and 2022 (in thousands):


	Balance at December 31, 2024		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Liabilities:
Warrant liability, related party (1)(2)	$	57	$	—	$	—	$	57
Warrant liability(1)	$	43	$	—	$	—	$	43
Total	$	100	$	—	$	—	$	100


(1)			Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
(2)			CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.


	Balance at December 31, 2023		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Warrant liability, related party (1)	$	110	$	—	$	—	$	110
Total	$	110	$	—	$	—	$	110

_____________________________


	Changes in Level 3 Instruments for the years ended December 31, 2024, 2023 and 2022
	Balance at January 1		Net Change in fair value included in earnings		Purchases / Issuance		Sales / Repurchases		Reclass		Balance at December 31, 2024
2024
Warrant liability, related party (1)(2)	$	110	$	150	$	—	$	—	$	(203)	$	57
Warrant liability(1)	—		(160)		—		—		203		43
Total	$	110	$	(10)	$	—	$	—	$	—	$	100

2023
Warrant liability, related party (1)	684		(574)		—		—				110
Total	$	684	$	(574)	$	—	$	—	$	—	$	110

2022
Warrant liability, related party (1)	1,262		(946)		368		—				684
Total	$	1,262	$	(946)	$	368	$	—	$	—	$	684


(1)			Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
(2)			CinRx is no longer deemed to be a related party. As a result the CinRx Warrants are no longer included.

There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the years ended December 31, 2024, 2023 and 2022. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other (expense) income, related party in the Consolidated Statements of Operations

The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility of the Company's common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants were:


	December 31, 2024		December 31, 2023
	Range	Weighted Average	Range	Weighted Average
Expected volatility	88.01% - 116.31%	105.97%	79.96% - 89.61%	81.55%
Risk-free interest rate	4.17% - 4.25%	4.23%	4.01% - 4.87%	4.15%


	December 31, 2024		December 31, 2023
Expected volatility	96.5	%	82.1	%
Expected life of options in years	2.5		3.5
Risk-free interest rate	4.3	%	4.0	%
Expected dividend yield	—	%	—	%

The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.

Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability. Gains and losses recognized due to the change in fair value of the warrant liability are recognized as a component of other (expense) income in the Consolidated Statements of Operations.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

Notes Payable

12 Months Ended

Dec. 31, 2024

Debt Disclosure [Abstract]

Notes Payable

Notes payable consist of the following (in thousands):


	December 31, 2024		December 31, 2023

Short-term financing	—		191
Total notes payable	—		191
Less: Current portion	—		(191)
Total notes payable, net of current portion	$	—	$	—

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Dec. 31, 2023	Nov. 20, 2023	Nov. 14, 2023	May 04, 2021	Dec. 31, 2020	Jul. 29, 2015
Common stock par value (usd per share)			$ 0.01
Class A Common Stock
Common stock par value (usd per share)	$ 0.01	$ 0.01		$ 0.01			$ 0.01
Common stock, shares authorized (in shares)	200,000,000	200,000,000	200,000,000	91,835,204	200,000,000	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	2,084,973	2,612,257
Class B Common Stock
Common stock par value (usd per share)	$ 0.01	$ 0.01		$ 0.01			$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000	100,000,000				100,000,000
Common stock, shares outstanding (in shares)	577,349	577,349

Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2024

Earnings Per Share [Abstract]

Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock


	Year Ended December 31,
	2024		2023(*)		2022(*)
Numerator:
Net loss	$	(22,705)	$	(25,966)	$	(25,073)
Less: Net loss attributable to noncontrolling interests	(4,243)		(5,716)		(5,909)
Net loss attributable to vTv Therapeutics Inc.	(18,462)		(20,250)		(19,164)

Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted	$	(18,462)	$	(20,250)	$	(19,164)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted (1)	5,771,052		2,084,973		1,919,788
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted	$	(3.20)	$	(9.71)	$	(9.98)
(*) Adjusted retroactively for reverse stock split, see Note 1


			(1)			The shares underlying the pre-funded warrants to purchase shares of the Company’s common stock have been included in the calculation of the weighted-average number of shares outstanding, basic and diluted, for the year ended December 31, 2024.

Schedule of Potentially Dilutive Securities not Included in Calculation of Dilutive Net Loss per Share

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:


	Year Ended December 31,
	2024	2023(*)	2022(*)
Class B common stock (1) (*)	577,349	577,349	577,349
Common stock options granted under the Plan (*)	705,593	249,247	208,586
Common stock warrants (*)	70,639	76,545	80,359
Total (*)	1,353,581	903,141	866,294
(*) Adjusted retroactively for reverse stock split, see Note 1

________________________________________________

not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.

Notes Payable (Tables)

12 Months Ended

Dec. 31, 2024

Debt Disclosure [Abstract]

Schedule of Notes Payable

Notes payable consist of the following (in thousands):


	December 31, 2024		December 31, 2023

Short-term financing	—		191
Total notes payable	—		191
Less: Current portion	—		(191)
Total notes payable, net of current portion	$	—	$	—

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

Stockholders’ Equity (Deficit) - Additional Information (Detail) $ / shares in Units, $ in Thousands									12 Months Ended
	Sep. 17, 2024 USD ($) shares	Feb. 27, 2024 $ / shares shares	Nov. 20, 2023 $ / shares shares	Nov. 14, 2023 $ / shares shares	Feb. 28, 2023 USD ($)	Jul. 22, 2022 USD ($) $ / shares shares	May 31, 2022 USD ($) shares	May 04, 2021 shares	Dec. 31, 2024 USD ($) Vote exercisable $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares	Dec. 31, 2022 USD ($)	Mar. 05, 2024 shares	Feb. 28, 2024 USD ($) Rate	Dec. 31, 2021 shares	Dec. 31, 2020 shares	Jul. 29, 2015 $ / shares shares
Class Of Stock [Line Items]
Preferred stock, shares authorized (in shares) \| shares			50,000,000													50,000,000
Common stock par value (usd per share) \| $ / shares			$ 0.01
Preferred stock par value (usd per share) \| $ / shares			$ 0.01													$ 0.01
Capital stock, shares authorized (in shares) \| shares								350,000,000						250,000,000
Preferred stock, shares outstanding (in shares) \| shares			0
Proceeds from collection of notes receivable					$ 12,000
Discount rate					3.75%
Gain (loss) on extinguishment of debt									$ 0	$ (313)	$ 0
letter agreement, maximum exercisable times \| exercisable									3
Related Party
Class Of Stock [Line Items]
Change in fair value of warrants									$ 150	(574)	(946)
Private Placement Pre-Funded Warrants
Class Of Stock [Line Items]
Class of warrant or right, percent of securities called by warrants or rights		9.99%							19.99%
Letter Agreement Warrants \| Related Party
Class Of Stock [Line Items]
Change in fair value of warrants									$ 200	$ (300)	$ (900)
TD Cowen Sales Agreement
Class Of Stock [Line Items]
Entity public float, threshold													$ 75,000
Commission percent \| Rate													3.00%
Private Placement
Class Of Stock [Line Items]
Common stock, par or stated value of private placement, shares (in shares) \| shares												(116,493)
Private placement pre-funded warrants, shares (in shares) \| shares												116,590
Private Placement \| Private Placement Pre-Funded Warrants
Class Of Stock [Line Items]
Exercise price of warrants (usd per share) \| $ / shares		$ 0.01
G42 Investments
Class Of Stock [Line Items]
Shares sold (in shares) \| shares							259,657
Sale of Stock, consideration received on transaction, gross							$ 25,000
Aggregate gross purchase price							12,500
Accounts and financing receivable, after allowance for credit loss							$ 12,500
Sale of stock, consideration, receivable, term							1 year
Proceeds from collection of notes receivable					$ 12,000
Discount rate					3.75%
Gain (loss) on extinguishment of debt					$ (300)
CinRx Investment
Class Of Stock [Line Items]
Shares sold (in shares) \| shares						103,864
Sale of Stock, consideration received on transaction, gross						$ 10,000
Aggregate gross purchase price						6,000
Accounts and financing receivable, after allowance for credit loss						$ 4,000
Expected life of options in years						5 years
Right of purchase of common stock from issuance of private placement, wait period		2 years
Class A Common Stock
Class Of Stock [Line Items]
Common stock, shares authorized (in shares) \| shares			200,000,000	91,835,204				200,000,000	200,000,000	200,000,000					100,000,000	100,000,000
Common stock par value (usd per share) \| $ / shares				$ 0.01					$ 0.01	$ 0.01						$ 0.01
Increase in shares authorized (in shares) \| shares								100,000,000
Stock split, conversion ratio			0.025	0.025
Common stock, vote per share \| Vote									1
Shares sold (in shares) \| shares	179,400
Aggregate gross purchase price	$ 2,500
Class A Common Stock \| TD Cowen Sales Agreement
Class Of Stock [Line Items]
Shares sold (in shares) \| shares									179,400
Aggregate gross purchase price									$ 2,500
Aggregate offering price													$ 50,000
Class A Common Stock \| Private Placement
Class Of Stock [Line Items]
Shares sold (in shares) \| shares		464,377
Share price (usd per share) \| $ / shares		$ 11.81
Class A Common Stock \| Private Placement \| Private Placement Pre-Funded Warrants
Class Of Stock [Line Items]
Share price (usd per share) \| $ / shares		$ 11.80
Warrants to purchase shares of common stock (in shares) \| shares		3,853,997							3,970,587
Class B Common Stock
Class Of Stock [Line Items]
Common stock, shares authorized (in shares) \| shares			100,000,000						100,000,000	100,000,000						100,000,000
Common stock par value (usd per share) \| $ / shares				$ 0.01					$ 0.01	$ 0.01						$ 0.01
Stock split, conversion ratio			0.025
Common stock, vote per share \| Vote									1
Common Stock
Class Of Stock [Line Items]
Common stock, shares authorized (in shares) \| shares								300,000,000						200,000,000
Common Stock \| CinRx Investment
Class Of Stock [Line Items]
Exercise price of warrants (usd per share) \| $ / shares						$ 28.80
Warrants to purchase shares of common stock (in shares) \| shares						30,000
Warrants and rights outstanding						$ 400

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On February 24, 2025, Steven Tuch, Executive Vice President and Chief Financial Officer of vTv Therapeutics Inc. (the "Company"), informed the Company of his intention to resign from his position effective March 21, 2025. Mr. Tuch is expected to remain at the Company through the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission. The Company has commenced efforts to identify Mr. Tuch's successor through an external search process. Mr. Tuch's departure is not based on any disagreement with the Company’s independent auditors or the Company on any matter.

Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value equity transfers in and out of level 3 instruments	$ 0	$ 0	$ 0
Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other income (expense), net
Significant Unobservable Inputs (Level 3)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 110,000	684,000	1,262,000
Net Change in fair value included in earnings	(10,000)	(574,000)	(946,000)
Purchases / Issuance	0	0	368,000
Sales / Repurchases	0	0	0
Fair value equity transfers in and out of level 3 instruments	0	0	0
Ending balance	100,000	110,000	$ 684,000
Significant Unobservable Inputs (Level 3) \| Related Party
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	110,000
Net Change in fair value included in earnings	150,000
Purchases / Issuance	0
Sales / Repurchases	0
Fair value equity transfers in and out of level 3 instruments	(203,000)
Ending balance	57,000	110,000
Significant Unobservable Inputs (Level 3) \| Nonrelated Party
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	0
Net Change in fair value included in earnings	(160,000)
Purchases / Issuance	0
Sales / Repurchases	0
Fair value equity transfers in and out of level 3 instruments	203,000
Ending balance	43,000	0
Fair Value, Measurements, Recurring
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	100,000	110,000
Fair Value, Measurements, Recurring \| Nonrelated Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	43,000
Fair Value, Measurements, Recurring \| Warrant Liability, Related Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:		110,000
Fair Value, Measurements, Recurring \| Common stock warrants \| Related Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	57,000
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	0	0
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Nonrelated Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	0
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Warrant Liability, Related Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:		0
Fair Value, Measurements, Recurring \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Common stock warrants \| Related Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	0
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2)
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	0	0
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| Nonrelated Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	0
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| Warrant Liability, Related Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:		0
Fair Value, Measurements, Recurring \| Significant Other Observable Inputs (Level 2) \| Common stock warrants \| Related Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	0
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3)
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	100,000	110,000
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3) \| Nonrelated Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	43,000
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3) \| Warrant Liability, Related Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:		$ 110,000
Fair Value, Measurements, Recurring \| Significant Unobservable Inputs (Level 3) \| Common stock warrants \| Related Party
Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]
Liabilities:	$ 57,000

Leases

12 Months Ended

Dec. 31, 2024

Leases [Abstract]

Leases

In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease included an option to renew for a five-year term as well as an option to terminate after three years, neither of which was recognized as part of its related right of use assets or lease liabilities as their election was not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. Further, the second amendment to the lease does not include any material residual value guarantee or restrictive covenants.

At December 31, 2024 and 2023, the weighted average incremental borrowing rate for operating leases held by the Company was 9.5%. At December 31, 2024 and 2023, the weighted average remaining lease terms for the operating leases held by the Company were 0.9 years and 1.9 years, respectively.

Maturities of lease liabilities for the Company’s operating leases as of December 31, 2024, were as follows (in thousands):


2025	$	177
2026	—
2027	—
2028	—
2029	—
Thereafter	—
Total lease payments	177
Less: imputed interest	(8)
Present value of lease liabilities	$	169

Operating lease cost was $0.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. During the years ended December 31, 2024 and December 31, 2023, cash paid for operating leases was $0.2 million.

Consolidated Statements of Changes in Redeemable Noncontrolling Interest and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands

Total

Redeemable Noncontrolling Interest

Class A Common Stock

Class B Common Stock

Common Stock

Class A Common Stock

Common Stock

Class B Common Stock

Additional Paid-in Capital

Class A Common Stock

Accumulated Deficit

Parent

Noncontrolling Interest

Beginning balance at Dec. 31, 2021

$ 24,962

Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]

Net loss

(5,909)

Ending balance at Dec. 31, 2022

16,579

Beginning balance, shares (in shares) at Dec. 31, 2021

1,721,452

577,349

Beginning balance at Dec. 31, 2021

$ (9,740)

$ 17

$ 6

$ 239,071

$ (248,834)

$ (9,740)

$ 0

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss

(19,164)

^[1]

(19,164)

Share-based compensation

1,272

Issuance of Class A common stock to collaboration agreement, net of offering costs (in shares)

259,657

Issuance of Class A common stock to collaboration agreement, net of offering costs

5,040

$ 3

5,037

5,040

Issuance of Class A Common Stock under CinRx purchase agreement, net of offering costs (in shares)

103,864

Issuance of Class A common stock under CinRx purchase agreement, net of offering costs

9,378

$ 1

9,377

9,378

Change in redemption value of noncontrolling interest

(2,474)

Change In Redemption Value Of Noncontrolling Interest

2,474

Ending balance, shares (in shares) at Dec. 31, 2022

2,084,973

577,349

Ending balance at Dec. 31, 2022

(10,740)

$ 21

$ 6

254,757

(265,524)

(10,740)

Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]

Net loss

(5,716)

Ending balance at Dec. 31, 2023

6,131

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss

(20,250)

^[1]

(20,250)

Share-based compensation

1,578

Change in redemption value of noncontrolling interest

(4,732)

Change In Redemption Value Of Noncontrolling Interest

4,732

Ending balance, shares (in shares) at Dec. 31, 2023

2,612,257

577,349

2,084,973

577,349

Ending balance at Dec. 31, 2023

(24,680)

$ 21

$ 6

256,335

(281,042)

(24,680)

Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]

Net loss attributable to redeemable noncontrolling interest

^[2]

(1,085)

Change in redemption value of redeemable noncontrolling interest

214

Ending balance at Dec. 31, 2024

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss

(18,462)

Share-based compensation

2,757

Change in redemption value of noncontrolling interest

(214)

Reclassifications of Temporary to Permanent Equity

5,260

$ (5,260)

5,260

Issuance of Class A common stock and pre-funded warrants, net offering costs (in shares)

347,884

Issuance of Class A common stock and pre-funded warrants, net offering costs

50,335

$ 3

$ 50,332

50,335

Issuance of Class A common stock under ATM offering (in shares)

179,400

Issuance of Class A Common Stock under ATM offering

2,463

$ 2

2,461

2,463

Change In Redemption Value Of Noncontrolling Interest

(3,158)

Ending balance, shares (in shares) at Dec. 31, 2024

2,084,973

577,349

2,612,257

577,349

Ending balance at Dec. 31, 2024

$ 14,301

$ 26

$ 6

$ 311,885

$ (299,718)

$ 12,199

$ 2,102

[1]	(*) Adjusted retroactively for reverse stock split
[2]	(*) Allocation of NCI net loss was a result from the reclassification to permanent equity on February 27, 2024 (See Note 12)

Related-Party Transactions - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2024 shares
Class A Common Stock \| Exchange of Redeemable Non controlling Interest To Class A Common Stock
Related Party Transaction [Line Items]
Stock conversion ratio	1
Related Party \| MacAndrews & Forbes Incorporated
Related Party Transaction [Line Items]
Ownership percentage of majority owner	46.70%
Amount of cash savings percentage	85.00%
Related Party \| Class B Common Stock \| MacAndrews & Forbes Incorporated
Related Party Transaction [Line Items]
Shares held by related party (in shares)	577,108
Related Party \| Class A Common Stock \| MacAndrews & Forbes Incorporated
Related Party Transaction [Line Items]
Shares held by related party (in shares)	912,982
Related Party \| Class A Common Stock \| Letter Agreements With MacAndrews
Related Party Transaction [Line Items]
Letter agreement time period	1 year
Related Party \| Class A Common Stock \| Exchange of Redeemable Non controlling Interest To Class A Common Stock \| MacAndrews & Forbes Incorporated
Related Party Transaction [Line Items]
Stock conversion ratio	1

Segment Information

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Segment Information

Our CODM is our President and Chief Executive Officer, Paul Sekhri. The CODM makes decisions on resource allocation, assesses performance of the business, and monitors budget versus actual results using net loss. Net loss is also a measure that is considered in monitoring budget versus actual results. The measure of the segment assets is reported on the consolidated balance sheet as total assets.

The Company manages its business activities on a consolidated basis and operates in a single reportable segment. Its operations primarily focus on the research and development of its lead product candidate, cadisegliatin, and it has not yet generated any revenue. All of the Company's principal operations, assets, and decision-making functions are based in the U.S., and as a result, all of our financial information is derived from domestic sources except for revenue of $1.0 million and $2.0 million during the years ended December 31, 2024 and 2022, respectively, which were derived from two foreign collaboration partners located in China.


	Years Ended December 31,
	2024		2023		2022
Direct research and development expense:
Cadisegliatin	6,026		10,182		9,611
Other projects*	490		676		563
Indirect research and development expense†	5,030		2,737		2,183
Total research and development expense	$	11,546	$	13,595	$	12,357


*			Includes HPP737 and azeliragon
†			Includes share-based compensation

Segment revenue is consistent with what is presented in the Company’s Consolidated Statements of Operations. Other segment items consist of (i) general and administrative expenses, which include share-based compensation, (ii) interest and other income (expense) and (iii) income tax expense, all of which are reflected in the Company’s Statements of Operations.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

+ Details

Pay vs Performance Disclosure - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Pay vs Performance Disclosure

Net loss

$ (18,462)

$ (20,250)

^[1]

$ (19,164)

^[1]

[1]	(*) Adjusted retroactively for reverse stock split

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Commitments and Contingencies - Additional Information (Detail) - Novo License Agreement $ in Millions	Feb. 28, 2007 USD ($)
Developmental And Regulatory Milestone Payment \| Maximum \| Type 1 Diabetes
Commitments And Contingencies [Line Items]
Potential milestone payment	$ 7.0
Developmental And Regulatory Milestone Payment \| Maximum \| Type 2 Diabetes
Commitments And Contingencies [Line Items]
Potential milestone payment	50.5
Developmental And Regulatory Milestone Payment \| Maximum \| Other Indication
Commitments And Contingencies [Line Items]
Potential milestone payment	115.0
Sales-based Milestones Payment
Commitments And Contingencies [Line Items]
Potential milestone payment	$ 75.0

Collaboration Agreements - Contract with Customer, Contract Asset, Contract Liability, and Receivable Changes (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
Revenue from Contract with Customer [Roll Forward]
Beginning balance	$ 18,686
Reclassification of the beginning contract liabilities to revenue, as the result of performance obligations satisfied	(17)
Ending balance	$ 18,669

Notes Payable - Schedule of Notes Payable (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Debt Disclosure [Abstract]
Short-term financing	$ 0	$ 191
Total notes payable	0	191
Less: Current portion	0	(191)
Total notes payable, net of current portion	$ 0	$ 0

Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Leases [Abstract]
2025	$ 177
2026	0
2027	0
2028	0
2029	0
Thereafter	0
Total lease payments	177
Less: imputed interest	(8)
Present value of lease liabilities	$ 169

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property and Equipment (Detail)	Dec. 31, 2024
Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	7 years
Computers and hardware \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Computers and hardware \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	5 years
Furniture and office equipment \| Minimum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Furniture and office equipment \| Maximum
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	7 years
Software
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	3 years
Leasehold improvements
Summary Of Significant Accounting Policies [Line Items]
Property and equipment, estimated useful lives	Useful Life, Lease Term [Member]

Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($)
$ / shares in Units, $ in Thousands

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Numerator:

Net loss

$ (22,705)

$ (25,966)

^[1]

$ (25,073)

^[1]

Less: Net loss attributable to noncontrolling interests

(4,243)

(5,716)

^[1]

(5,909)

^[1]

Net loss attributable to vTv Therapeutics Inc.

(18,462)

(20,250)

^[1]

(19,164)

^[1]

Net loss attributable to common shareholders of vTv Therapeutics Inc., basic

(18,462)

(20,250)

^[1]

(19,164)

^[1]

Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted

$ (18,462)

$ (20,250)

$ (19,164)

Class A Common Stock

Denominator:

Weighted average number of vTv Therapeutics Inc. Class A Common Stock, basic (in shares)

5,771,052

2,084,973

^[1]

1,919,788

^[1]

Weighted average number of vTv Therapeutics Inc. Class A Common Stock, diluted (in shares)

5,771,052

2,084,973

^[1]

1,919,788

^[1]

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic (usd per share)

$ (3.20)

$ (9.71)

^[1]

$ (9.98)

^[1]

Net loss per share of vTv Therapeutics Inc. Class A Common Stock, diluted (usd per share)

$ (3.20)

$ (9.71)

^[1]

$ (9.98)

^[1]

[1]	(*) Adjusted retroactively for reverse stock split

Noncontrolling Interest (Tables)

12 Months Ended

Dec. 31, 2024

Noncontrolling Interest [Abstract]

Summary of Net Income Attributable to Vtv Therapeutics Inc

The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:


	December 31,
	2024		2023		2022
Net loss attributable to vTv Therapeutics Inc. common shareholders	$	(18,462)	$	(20,250)	$	(19,164)
Decrease in vTv Therapeutics Inc. stockholders' equity (deficit) for sale of vTv Units as a result of common stock issuances	(7,592)		—		(1,061)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest	$	(26,054)	$	(20,250)	$	(20,225)

Income Taxes - Additional Information (Detail) - USD ($)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

^[1]

Income Taxes [Line Items]

Income tax provision

$ 100,000

$ 0

^[1]

$ 200,000

Increase in valuation allowance

5,000,000.0

Tax credit carryforward

2,491,000

$ 2,215,000

Uncertain tax positions

Increase decrease in uncertain tax position reasonably possible

Domestic Tax Jurisdiction

Income Taxes [Line Items]

Net operating loss carryforwards

125,800,000

Domestic Tax Jurisdiction | Research And Development

Income Taxes [Line Items]

Tax credit carryforward

2,500,000

State and Local Jurisdiction

Income Taxes [Line Items]

Net operating loss carryforwards

59,700,000

Expire in 2035 to 2037 | Domestic Tax Jurisdiction

Income Taxes [Line Items]

Net operating loss carryforwards

$ 38,800,000

Maximum percentage of taxable income limited to offset by net operating loss carryforwards

100.00%

Indefinite | Domestic Tax Jurisdiction

Income Taxes [Line Items]

Net operating loss carryforwards

$ 86,900,000

Maximum percentage of taxable income limited to offset by net operating loss carryforwards

80.00%

M&F TTP Holdings LLC

Income Taxes [Line Items]

Amount of cash savings percentage

85.00%

[1]	(*) Adjusted retroactively for reverse stock split

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Accounts payable	$ 939	$ 4,075
Accrued development costs	2,263	4,401
Accrued compensation and related costs	1,509	1,466
Accrued other	316	300
Total	$ 5,027	$ 10,242

Share-Based Compensation - Assumptions Used to Estimate Fair Value of Stock Option Awards Granted (Detail)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected volatility, minimum	96.84%	121.01%	118.72%
Expected volatility, maximum	108.61%	126.76%	128.72%
Risk-free interest rate, minimum	3.44%	3.42%	1.59%
Risk-free interest rate, maximum	4.36%	4.61%	4.31%
Expected dividend yield	0.00%	0.00%	0.00%
Minimum
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected life of option, in years	5 years 6 months	5 years 6 months	5 years 2 months 12 days
Maximum
Schedule of Share Based Compensation Valuation Assumptions [Line Items]
Expected life of option, in years	6 years 1 month 6 days	6 years 1 month 6 days	6 years 1 month 6 days

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid insurance	$ 577	$ 680
Prepaid - other	643	364
Total	$ 1,220	$ 1,044

Summary of Significant Accounting Policies - Additional Information (Detail)

12 Months Ended

Dec. 31, 2024

USD ($)

Segment

Rate

Dec. 31, 2023

USD ($)

Dec. 31, 2022

USD ($)

Summary Of Significant Accounting Policies [Line Items]

Revenue

$ 1,017,000

$ 0

^[1]

$ 2,018,000

^[1]

Asset impairment charges

$ 0

Assets held for sale

$ 0

Significant interest or penalties incurred related to income taxes

$ 0

Number of reportable segment | Segment

Number of operating segments | Segment

vTv Therapeutics LLC

Summary Of Significant Accounting Policies [Line Items]

Subsidiary, ownership percentage, noncontrolling owner | Rate

18.10%

Minimum

Summary Of Significant Accounting Policies [Line Items]

Property and equipment, estimated useful lives

3 years

Maximum

Summary Of Significant Accounting Policies [Line Items]

Property and equipment, estimated useful lives

7 years

Revenue | Customer | Two Customers

Summary Of Significant Accounting Policies [Line Items]

Concentration risk percentage

100.00%

Revenue | Customer | One Customer

Summary Of Significant Accounting Policies [Line Items]

Concentration risk percentage

100.00%

[1]	(*) Adjusted retroactively for reverse stock split

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Income Tax Disclosure [Abstract]

U.S. statutory tax benefit

$ (4,747)

$ (5,453)

$ (5,223)

Partnership income (federal) not subject to tax to the Company

891

1,200

1,241

Foreign withholding tax

158

State taxes (net of federal benefit)

(928)

(2)

Research and development tax credit

(373)

(273)

(172)

Other

190

(64)

Change in valuation allowance

4,988

4,592

4,128

Provision for income taxes

$ 100

$ 0

^[1]

$ 200

^[1]

Effective income tax rate

(0.40%)

0.00%

(0.80%)

[1]	(*) Adjusted retroactively for reverse stock split

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true